Invion Limited (ASX: IVX) has successfully raised AU$0.8 million before costs by issuing Convertible Notes, aimed at strengthening its capital base. The fundraising was led by Summit Biotech Fund and a specialized microcap fund, with additional participation from sophisticated investors. The funds will primarily be utilized to settle outstanding liabilities with Lind Global Fund II LP and support general working capital.
The Convertible Notes are set to automatically convert into equity at a conversion price defined by a ceiling and floor range. The conversion is expected to occur either on or before 28 February 2026 or when the Photosoft™ Licensing Agreement is executed. Invion’s Executive Chair and CEO, Prof Thian Chew, highlighted the company's growth potential and the opportunity to secure global licensing agreements for the Photosoft™ technology in therapeutics and diagnostics. The issuance of the Convertible Notes will take place without requiring shareholder approval, within the company’s current placement capacity. This funding represents a significant step in Invion’s strategic development, contributing to the company’s future growth plans.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Oct 10, 2025
Oct 10, 2025
Oct 10, 2025
Oct 10, 2025
Oct 10, 2025
Oct 10, 2025
Oct 10, 2025
Oct 10, 2025
Oct 10, 2025
Oct 10, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
